Exhibit 99.1 MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Post-bariatric Hypoglycemia (PBH): MBX 1416 • Phase 2 trial expected to be initiated in 2H 2025: In January, MBX reported Phase 1 top line results for its MBX 1416 long-acting GLP-1 receptor antagonist developed for the treatment of PBH. A Phase 2 trial is expected to be initiated in t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Commission | Exact name of registrant as specified in its charter and | | | State of | I.R.S. | | --- | --- | --- | --- | --- | --- | | File Number | principal of ice address and telephone number | ...

Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE May 12, 2025 CENTURI REPORTS FIRST QUARTER 2025 RESULTS, AFFIRMS 2025 OUTLOOK PHOENIX, AZ – May 12, 2025 - Centuri Holdings, Inc. (NYSE: CTRI) ("Centuri" or the "Company") today announced financial and operating results for the first quarter, ended March 30, 2025, and affirms full year 2025 outlook. First Quarter 2025 Financial and Other Business Highlights Contacts: For Centuri investors, contact: For Centuri media information, contact: (623) 879-3700 Jennif ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number 001-41775 NEURAXIS, INC. (Exact name of registrant as specified in its charter) | Delaware | 45-50 ...

Exhibit 99.1 IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated im ...

Financial Performance - Fox Corporation reported total quarterly revenues of $4.37 billion, an increase of $924 million or 27% from the prior year quarter[3]. - Advertising revenues increased by 65% to $2.04 billion, primarily due to Super Bowl LIX and digital growth from the Tubi AVOD service[3]. - Quarterly net income was $354 million, down from $704 million in the prior year quarter, with adjusted net income of $507 million[4]. - Adjusted EBITDA for the quarter was $856 million, a decrease of $35 million or 4% from the prior year quarter[4]. - Cable Network Programming segment revenues increased by 11% to $1.64 billion, with advertising revenues up 26%[9]. - Television segment revenues rose by 40% to $2.70 billion, driven by a 77% increase in advertising revenues[12]. - Adjusted net income for the three months ended March 31, 2025, was $507 million, compared to $520 million for the same period in 2024, reflecting a decrease of 2.5%[28]. Shareholder Value - The company repurchased approximately $250 million of its Class A common stock during the quarter, with a total repurchase of $5.35 billion to date[15]. - The company repurchased shares worth $750 million during the nine months ended March 31, 2025[24]. - Fox Corporation maintains a robust balance sheet and is positioned to drive long-term value for shareholders[4]. Assets and Liabilities - Total assets increased to $23,367 million as of March 31, 2025, up from $21,972 million on June 30, 2024, representing a growth of 6.34%[22]. - Total current liabilities rose to $3,567 million as of March 31, 2025, compared to $2,952 million on June 30, 2024, marking an increase of 20.8%[22]. - Total equity increased to $11,638 million as of March 31, 2025, up from $10,814 million on June 30, 2024, indicating a growth of 7.6%[22]. - The company’s borrowings remained stable at $6,601 million for non-current liabilities, with a slight increase from $6,598 million on June 30, 2024[22]. Cash Flow - Cash and cash equivalents at the end of the period were $4,815 million, an increase of 11.5% from $4,319 million at the beginning of the year[24]. - The company reported a net cash provided by operating activities of $1,811 million for the nine months ended March 31, 2025, compared to $941 million for the same period in 2024, an increase of 92.7%[24]. Expenses - The company experienced higher expenses due to increased sports programming rights amortization and production costs related to Super Bowl LIX[4].

Financial Performance - Fox Corporation reported total quarterly revenues of $4.37 billion, an increase of $924 million or 27% from the prior year quarter[3]. - Quarterly net income was $354 million, down from $704 million in the prior year quarter, with adjusted net income attributable to stockholders at $507 million[4]. - Adjusted EBITDA for the quarter was $856 million, a decrease of $35 million or 4% from the prior year quarter, primarily due to higher expenses[4]. - Affiliate fee revenues increased by 3% to $2.00 billion, while advertising revenues surged by 65% to $2.04 billion, driven by Super Bowl LIX and digital growth[3][6]. - Television segment revenues rose by 40% to $2.70 billion, with advertising revenues increasing by 77% due to the Super Bowl and Tubi AVOD service growth[12]. - Cable Network Programming reported quarterly segment revenues of $1.64 billion, an increase of 11% from the prior year quarter[8]. - The company reported a record free cash flow, underscoring its strong financial performance and robust balance sheet[4]. - Net income for the nine months ended March 31, 2025, was $1,574 million, a 27.6% increase compared to $1,234 million for the same period in 2024[24]. - Adjusted EBITDA for the three months ended March 31, 2025, was $856 million, compared to $891 million for the same period in 2024, reflecting a decrease of 3.93%[33]. - The company reported an adjusted net income of $507 million for the three months ended March 31, 2025, slightly down from $520 million in the same period of 2024[28]. Shareholder Actions - The company has repurchased approximately $5.35 billion of its Class A common stock and $1 billion of its Class B common stock, with a remaining authorization of $650 million[15]. - The company repurchased shares worth $750 million during the nine months ended March 31, 2025, consistent with the previous year[24]. Balance Sheet and Assets - Total assets increased to $23,367 million as of March 31, 2025, up from $21,972 million on June 30, 2024, representing an increase of 6.34%[22]. - Cash and cash equivalents increased to $4,815 million at the end of the period, up from $4,319 million at the beginning of the year, marking a net increase of $496 million[24]. - Total current liabilities rose to $3,567 million as of March 31, 2025, compared to $2,952 million on June 30, 2024, an increase of 20.8%[22]. - Total equity increased to $11,638 million as of March 31, 2025, compared to $10,814 million on June 30, 2024, an increase of 7.63%[22]. - The company’s total liabilities increased to $11,829 million as of March 31, 2025, compared to $10,318 million on June 30, 2024, reflecting an increase of 14.6%[22]. Future Outlook - Future outlook remains positive, with confidence in best-in-class assets and deliberate strategy to drive long-term shareholder value[4]. - The company’s net cash provided by operating activities for the nine months ended March 31, 2025, was $1,811 million, significantly higher than $941 million for the same period in 2024[24].

Southwest Gas Holdings, Inc. Reports First Quarter 2025 Financial Results, Reaffirms Guidance Delivers a Last-Twelve-Months' Utility ROE of 8.2% and Earnings Growth of 5.2% over 1Q 2024 Receives ~$80.2 Million Annual Revenue Increase from Completed Arizona Rate Case LAS VEGAS – May 12, 2025 – Southwest Gas Holdings, Inc. (NYSE: SWX) ("Southwest Gas Holdings" or "Company") today reported results for its first quarter ended March 31, 2025. This earnings press release should be read in conjunction with the For ...

PRINCETON, N.J. May 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent developments. "We are entering a pivotal and exciting period for UroGen as we approach the anticipated FDA approval of our lead pipeline product, UGN-102, in June for recurrent low-grade intermediate-risk ...